DelveInsight’s ‘Focal Segmental Glomerulosclerosis (FSGS)—Market Insights, Epidemiology, and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Focal Segmental Glomerulosclerosis from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2028
Focal Segmental Glomerulosclerosis - Disease Understanding and Treatment Algorithm
The DelveInsight Focal Segmental Glomerulosclerosis market report gives a thorough understanding of FSGS by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Focal Segmental Glomerulosclerosis in the US, Europe, and Japan.
Focal Segmental Glomerulosclerosis Epidemiology
The Focal Segmental Glomerulosclerosis epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Total Prevalent cases, Gender-specific cases, Type-specific cases [Primary, Secondary] and Age-specific cases [Children, Adult] in the 7MM.
According to DelveInsight, the total prevalent cases of Focal Segmental Glomerulosclerosis were 196,333 in 2017 in 7MM.
Focal Segmental Glomerulosclerosis Drug Chapters
This segment of the Focal Segmental Glomerulosclerosis report encloses the detailed analysis of marketed drugs and late-stage (Phase-II and III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Focal Segmental Glomerulosclerosis Market Outlook
The Focal Segmental Glomerulosclerosis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Currently, there are no FDA-approved therapies for FSGS. The therapeutic market size of FSGS in the US is mainly accounted for by the off-label treatment options, such as non-immune therapy in conjunction with immunotherapy. The non-immune therapy includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers as the conservative treatment options. While, the immunotherapy includes, corticosteroids (Prednisone), calcineurin inhibitors (Cyclosporine and Tacrolimus), Mycophenolate Mofetil, and Biologics (rituximab), for those seriously ill patients. Kidney transplantation is the viable treatment options for children. In case of recurrence, plasmapheresis is the first-line treatment along with dialysis. Despite these available treatments, the management of FSGS remains a challenge due to the complex causes of disease and dense pathogenesis.
As per DelveInsight estimates, the market size of FSGS was found to be USD 333.36 Million in 2017. This market is further expected to grow during the forecasted period of 2019–2028 owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies, including Sparsentan (Retrophin), DMX-200 (Dimerix), Voclosporin (Aurinia Pharmaceuticals), CXA-10 (Complexa), Abatacept (Bristol-Myers Squibb), Bardoxolone methyl (Reata Pharmaceuticals/Kyowa Kirin), PF-06730512 (Pfizer), CCX140 (Chemocentryx) etc. are also provided in the report.
Focal Segmental Glomerulosclerosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on the market share and size, which again will be useful in investigating factors, vital in market uptake and in making financial and regulatory decisions.
Focal Segmental Glomerulosclerosis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Focal Segmental Glomerulosclerosis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Focal Segmental Glomerulosclerosis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
• Organize sales and marketing efforts by identifying the best opportunities for Focal Segmental Glomerulosclerosis market.
• To understand the future market competition in the Focal Segmental Glomerulosclerosis market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook